Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 37
Filter
1.
Antimicrob Agents Chemother ; 68(5): e0131523, 2024 May 02.
Article in English | MEDLINE | ID: mdl-38517189

ABSTRACT

Chromosomal and transferable AmpC ß-lactamases represent top resistance mechanisms in different gram-negatives, but knowledge regarding the latter, mostly concerning regulation and virulence-related implications, is far from being complete. To fill this gap, we used Klebsiella pneumoniae (KP) and two different plasmid-encoded AmpCs [DHA-1 (AmpR regulator linked, inducible) and CMY-2 (constitutive)] as models to perform a study in which we show that blockade of peptidoglycan recycling through AmpG permease inactivation abolished DHA-1 inducibility but did not affect CMY-2 production and neither did it alter KP pathogenic behavior. Moreover, whereas regular production of both AmpC-type enzymes did not attenuate KP virulence, when blaDHA-1 was expressed in an ampG-defective mutant, Galleria mellonella killing was significantly (but not drastically) attenuated. Spontaneous DHA-1 hyperproducer mutants were readily obtained in vitro, showing slight or insignificant virulence attenuations together with high-level resistance to ß-lactams only mildly affected by basal production (e.g., ceftazidime, ceftolozane/tazobactam). By analyzing diverse DHA-1-harboring clinical KP strains, we demonstrate that the natural selection of these hyperproducers is not exceptional (>10% of the collection), whereas mutational inactivation of the typical AmpC hyperproduction-related gene mpl was the most frequent underlying mechanism. The potential silent dissemination of this kind of strains, for which an important fitness cost-related contention barrier does not seem to exist, is envisaged as a neglected threat for most ß-lactams effectiveness, including recently introduced combinations. Analyzing whether this phenomenon is applicable to other transferable ß-lactamases and species as well as determining the levels of conferred resistance poses an essential topic to be addressed.IMPORTANCEAlthough there is solid knowledge about the regulation of transferable and especially chromosomal AmpC ß-lactamases in Enterobacterales, there are still gaps to fill, mainly related to regulatory mechanisms and virulence interplays of the former. This work addresses them using Klebsiella pneumoniae as model, delving into a barely explored conception: the acquisition of a plasmid-encoded inducible AmpC-type enzyme whose production can be increased through selection of chromosomal mutations, entailing dramatically increased resistance compared to basal expression but minor associated virulence costs. Accordingly, we demonstrate that clinical K. pneumoniae DHA-1 hyperproducer strains are not exceptional. Through this study, we warn for the first time that this phenomenon may be a neglected new threat for ß-lactams effectiveness (including some recently introduced ones) silently spreading in the clinical context, not only in K. pneumoniae but potentially also in other pathogens. These facts must be carefully considered in order to design future resistance-preventive strategies.


Subject(s)
Anti-Bacterial Agents , Bacterial Proteins , Klebsiella pneumoniae , Membrane Transport Proteins , Microbial Sensitivity Tests , Peptidoglycan , Plasmids , beta-Lactamases , Klebsiella pneumoniae/drug effects , Klebsiella pneumoniae/genetics , Klebsiella pneumoniae/pathogenicity , Klebsiella pneumoniae/metabolism , Peptidoglycan/metabolism , Bacterial Proteins/genetics , Bacterial Proteins/metabolism , Virulence , beta-Lactamases/genetics , beta-Lactamases/metabolism , Anti-Bacterial Agents/pharmacology , Plasmids/genetics , Animals , Klebsiella Infections/microbiology , Moths/microbiology
2.
Int J Antimicrob Agents ; 62(1): 106836, 2023 Jul.
Article in English | MEDLINE | ID: mdl-37150362

ABSTRACT

The need for alternative drugs to treat methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia has led to a focus on ceftaroline, for which clinical data remain scarce. Herein, the efficacy of ceftaroline fosamil for the treatment of experimental MRSA bacteraemia was compared with that of approved therapies. Five MRSA strains were tested in an immunocompetent BALB/c bacteraemia model. Serum pharmacokinetics of ceftaroline fosamil were determined using HPLC/MS Q-TOF. Two hours after infection with the MRSA strains, mice were administered 50 mg/kg of ceftaroline fosamil every 6 h, for 24 h. This regimen yielded a T>MIC of 61.5% for an MIC of 1 mg/L and proved efficacious against all strains, including an hVISA strain with non-susceptibility to daptomycin, as indicated by the reduction (mean ± s.d.) in log10 CFU/mL in blood of 2.34 ± 0.33 and log10 CFU/g in kidney of 2.08 ± 0.22. Similarly, treatment with daptomycin yielded a log reduction of 2.30 ± 0.60 in blood and 2.14 ± 0.31 in kidney. The decrease in bacterial density was less accentuated after treatment with vancomycin, which yielded 1.84 ± 0.73 and 1.95 ± 0.32 log reductions in blood and kidney, respectively. The results of the study showed that the efficacy of ceftaroline fosamil against MRSA bacteraemia in mice is not inferior to that of vancomycin and daptomycin, and indicated the potential use of ceftaroline fosamil against difficult-to-treat S. aureus bacteraemia. Considering these promising data, clinical trials should be conducted to ascertain the efficacy of the drug for treating bloodstream infections in humans.


Subject(s)
Bacteremia , Daptomycin , Methicillin-Resistant Staphylococcus aureus , Staphylococcal Infections , Humans , Animals , Mice , Vancomycin/therapeutic use , Vancomycin/pharmacokinetics , Daptomycin/therapeutic use , Daptomycin/pharmacokinetics , Anti-Bacterial Agents/therapeutic use , Anti-Bacterial Agents/pharmacokinetics , Bacteremia/drug therapy , Bacteremia/microbiology , Disease Models, Animal , Staphylococcal Infections/drug therapy , Staphylococcal Infections/microbiology , Staphylococcus aureus , Cephalosporins/therapeutic use , Cephalosporins/pharmacokinetics , Microbial Sensitivity Tests , Ceftaroline
3.
ACS Omega ; 7(36): 31897-31904, 2022 Sep 13.
Article in English | MEDLINE | ID: mdl-36119989

ABSTRACT

We report a facile, economic, and ecofriendly method for selective recovery of Er, Gd, Sn, and In from liquid crystal display (LCD) screen wastes by ultrasound-assisted leaching, followed by magnetic separation. Thermodynamic analysis showed that the pyrophosphate ion is an excellent leaching agent for Er, Gd, and In at pH values below 8. Dissolved screen waste powder was subjected to leaching at room temperature using aqueous solutions of 0.05 M of sodium pyrophosphate (Na4P2O7) as the leaching agent; hydrogen peroxide (H2O2) (3 v/v %) was added as an auxiliary reducing agent, and an ultrasonic source was used in the process. Once completed, magnetic separation was applied to the leached residue. The average contents of Er, In, Sn, and Gd in the LCD screen were found to be 477, 2422, 835, and 93 mg·kg-1, respectively, of which 93, 97, 72, and 99% were selectively recovered from the waste material by this method at pH 3 after 2 h of leaching. The proposed method emerges as an easy and selective process for leaching Er from LCD screen wastes and concentrating In, Sn, and Gd in a separable magnetic solid.

4.
Cir Esp (Engl Ed) ; 100(6): 352-358, 2022 Jun.
Article in English | MEDLINE | ID: mdl-35580757

ABSTRACT

INTRODUCTION: The COVID-19 pandemic led to the cancellation of non-essential surgical procedures in March 2020. With the resumption of surgical activity, patients undergoing surgery were one of the first population groups to be systematically tested for PCR. The aim of this study was to determine the prevalence of asymptomatic SARS-CoV-2 carriers after the resumption of non-essential surgical activity. METHODS: Retrospective multicenter observational study of patients scheduled for surgery or undergoing emergency surgery in Catalonia between 20 April and 31 May 2020. The microbiological results of preoperative PCR tests and clinical records were reviewed, and an epidemiological survey was conducted on patients with positive PCR for SARS-CoV-2. RESULTS: A total of 10,838 patients scheduled for surgery or who underwent emergency surgery were screened for COVID-19. One hundred and eighteen patients (1.09%) were positive for SARS-CoV-2 in the 72 h prior to surgery. The prevalence of asymptomatic carriers was 0.7% (IC95%: 0.6%-0.9%). The first week of the study presented the highest prevalence of asymptomatic carriers [1.9% (CI95%:1.1%-3.2%)]. CONCLUSIONS: The low levels of asymptomatic carriers of COVID-19 infection obtained in the surgical population of hospitals in Catalonia after the resumption of surgical activity, shows that most patients were able to undergo surgical procedures without the risks of COVID-19 associated complications in the perioperative period.


Subject(s)
COVID-19 , COVID-19/epidemiology , Hospitals , Humans , Pandemics , Prevalence , SARS-CoV-2 , Spain/epidemiology
5.
Antibiotics (Basel) ; 11(5)2022 Apr 30.
Article in English | MEDLINE | ID: mdl-35625251

ABSTRACT

The antimicrobial and immunomodulatory capacities of the peptide Css54 and the chemokine MCP-1 were tested. The first, a peptide isolated from the venom of the scorpion Centruroides suffusus suffusus was synthesized chemically. In contrast, the second is a monocyte chemoattractant expressed as a recombinant protein in our lab. It was observed in vitro that Css54 inhibited the growth of Salmonella enterica serovar Typhimurium (6.2 µg/mL). At high concentrations, it was toxic to macrophages (25 µg/mL), activated macrophage phagocytosis (1.5 µg/mL), and bound Salmonella LPS (3 µg/mL). On the other hand, the recombinant MCP-1 neither inhibited the growth of Salmonella Typhimurium nor was it toxic to macrophages (up to 25 µg/mL), nor activated macrophage phagocytosis or bound Salmonella LPS (up to 3 µg/mL). Although it was observed in vivo in mice Balb/C that both Css54 and MCP-1 did not resolve the intraperitoneal infection by S. Typhimurium, Css54 decreased the expression of IL-6 and increased IL-10, IL-12p70, and TNF-α levels; meanwhile, MCP-1 decreased the expression of IFN-γ and increased IL-12p70 and TNF-α. It was also observed that the combination of both molecules Css54 and MCP-1 increased the expression of IL-10 and TNF-α.

6.
Int J Antimicrob Agents ; 59(1): 106456, 2022 Jan.
Article in English | MEDLINE | ID: mdl-34688835

ABSTRACT

The emergence of 16S rRNA methyltransferases (RMTs) in Gram-negative pathogens bearing other clinically relevant resistance mechanisms, such as carbapenemase-producing Enterobacterales (CPE), is becoming an alarming concern. We investigated the prevalence, antimicrobial susceptibility, resistance mechanisms, molecular epidemiology and genetic support of RMTs in CPE isolates from Spain. This study included a collection of 468 CPE isolates recovered during 2018 from 32 participating Spanish hospitals. MICs were determined using the broth microdilution method, the agar dilution method (fosfomycin) or MIC gradient strips (plazomicin). All isolates were subjected to hybrid whole-genome sequencing (WGS). Sequence types (STs), core genome phylogenetic relatedness, horizontally acquired resistance mechanisms, plasmid analysis and the genetic environment of RMTs were determined in silico from WGS data in all RMT-positive isolates. Among the 468 CPE isolates evaluated, 24 isolates (5.1%) recovered from nine different hospitals spanning five Spanish regions showed resistance to all aminoglycosides and were positive for an RMT (21 RmtF, 2 ArmA and 1 RmtC). All RMT-producers showed high-level resistance to all aminoglycosides, including plazomicin, and in most cases exhibited an extensively drug-resistant susceptibility profile. The RMT-positive isolates showed low genetic diversity and were global clones of Klebsiella pneumoniae (ST147, ST101, ST395) and Enterobacter cloacae (ST93) bearing blaOXA-48, blaNDM-1 or blaVIM-1 carbapenemase genes. RMTs were harboured in five different multidrug resistance plasmids and linked to efficient mobile genetic elements. Our findings highlight that RMTs are emerging among clinical CPE isolates from Spain and their spread should be monitored to preserve the future clinical utility of aminoglycosides and plazomicin.


Subject(s)
Drug Resistance, Bacterial/genetics , Enterobacteriaceae/genetics , Enterobacteriaceae/metabolism , Methyltransferases/genetics , Methyltransferases/metabolism , RNA, Ribosomal, 16S/genetics , beta-Lactamases/genetics , beta-Lactamases/metabolism , Genetic Variation , Genome-Wide Association Study , Genotype , Humans , Spain
7.
Plants (Basel) ; 10(12)2021 Dec 17.
Article in English | MEDLINE | ID: mdl-34961272

ABSTRACT

An extraction method was designed and scaled up to produce multicomponent polyphenolic extracts from blueberries (Vaccinium corymbosum) of three different varieties. The process was specifically drawn up to comply with green chemistry principles. Extracts were obtained for the direct assessment of their antimicrobial and antiadhesive activities, and their direct use in the control of infections caused by concerning multidrug-resistant nosocomial pathogens. Analytical characterization was performed by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Similar qualitative profiles were obtained in the three studied varieties with some significant quantitative differences. Up to 22 different polyphenols were identified with a clear predominance of anthocyani(di)ns followed by flavanols, non-flavonoids, and far behind by flavan-3-ols and procyanidins. The individual content of the main polyphenols was also discussed. A pilot scale extract has been also produced as a proof-of-concept, showing that scaling-up triples the content of bioactive phytochemicals. The effect of the polyphenolic extracts was analyzed against seven multidrug-resistance bacterial species by performing biofilm formation and growth and killing curves assays. All the studied varieties showed antibacterial and antiadhesive activities, being the extract containing the highest concentration of bioactive polyphenols, the most active with a high bactericidal effect.

8.
Rev Med Inst Mex Seguro Soc ; 59(2): 127-132, 2021 Jun 14.
Article in Spanish | MEDLINE | ID: mdl-34231984

ABSTRACT

BACKGROUND: Infections increase morbidity and mortality in patients with autoimmune disorders; however, this association has not been established in rheumatic diseases and SARS-CoV-2 infection. OBJECTIVE: To describe the clinical characteristics and mortality of patients with rheumatic diseases and severe COVID-19. MATERIAL AND METHODS: Observational and descriptive case series in patients with rheumatic diseases and severe SARS-CoV-2 infection, confirmed by PCR or pulmonary tomography, hospitalized in Mexico City from March to August 2020. RESULTS: 15 patients with a mean age of 57 years (SD ± 11) were included, 66.6% were women, and 80% had a positive PCR test. The time from onset of symptoms to hospitalization, on average, was 7.2 days (SD ± 2.1). 46.6% died. Patients who died had a lower mean platelet level compared to survivors. The inflammatory reactants were higher in the deceased. There were no statistically significant differences in mortality for the variables related to rheumatic disease. CONCLUSIONS: The differences in mortality of patients with severe COVID-19 in this series of cases seem to be related to the infection and not to the rheumatic disease.


INTRODUCCIÓN: las infecciones incrementan la morbimortalidad de los pacientes con trastornos autoinmunes; sin embargo, esta asociación no ha sido establecida en enfermedades reumáticas e infección por SARS-CoV-2. OBJETIVO: describir las características clínicas y la mortalidad de pacientes con enfermedades reumáticas y COVID-19 grave. MATERIAL Y MÉTODOS: serie de casos observacional y descriptiva, en pacientes con enfermedades reumáticas e infección grave por SARS-CoV-2, confirmada por PCR o tomografía pulmonar, hospitalizados en la Ciudad de México de marzo a agosto de 2020. RESULTADOS: se incluyeron 15 pacientes con edad media de 57 años (DE ± 11), el 66.6% eran mujeres, el 80% tuvieron prueba de PCR positiva. El tiempo de inicio de síntomas hasta la hospitalización, en promedio, fue de 7.2 días (DE ± 2.1). Falleció el 46.6%. Los pacientes que murieron tenían un nivel medio de plaquetas más bajo en comparación con los sobrevivientes. Los reactantes inflamatorios fueron más altos en los fallecidos. No hubo diferencias estadísticamente significativas en cuanto a la mortalidad para las variables relacionadas a la enfermedad reumática. CONCLUSIONES: las diferencias en mortalidad de pacientes con COVID-19 grave en esta serie de casos parecen estar relacionadas con la infección y no con la enfermedad reumática.


Subject(s)
COVID-19 , Rheumatic Diseases , Female , Hospitalization , Humans , Mexico/epidemiology , Middle Aged , Rheumatic Diseases/complications , Rheumatic Diseases/diagnosis , SARS-CoV-2
9.
J Med Chem ; 64(9): 6310-6328, 2021 05 13.
Article in English | MEDLINE | ID: mdl-33913328

ABSTRACT

Pseudomonas aeruginosa, a major cause of nosocomial infections, is considered a paradigm of antimicrobial resistance, largely due to hyperproduction of chromosomal cephalosporinase AmpC. Here, we explore the ability of 6-pyridylmethylidene penicillin-based sulfones 1-3 to inactivate the AmpC ß-lactamase and thus rescue the activity of the antipseudomonal ceftazidime. These compounds increased the susceptibility to ceftazidime in a collection of clinical isolates and PAO1 mutant strains with different ampC expression levels and also improved the inhibition kinetics relative to avibactam, displaying a slow deacylation rate and involving the formation of an indolizine adduct. Bromide 2 was the inhibitor with the lowest KI (15.6 nM) and the highest inhibitory efficiency (kinact/KI). Computational studies using diverse AmpC enzymes revealed that the aromatic moiety in 1-3 targets a tunnel-like site adjacent to the catalytic serine and induces the folding of the H10 helix, indicating the potential value of this not-always-evident pocket in drug design.


Subject(s)
Immunity, Innate/drug effects , Penicillins/chemistry , Penicillins/pharmacology , Pseudomonas aeruginosa/drug effects , Sulfones/chemistry , beta-Lactam Resistance/drug effects , Anti-Bacterial Agents/chemistry , Anti-Bacterial Agents/pharmacology , Bacterial Proteins/antagonists & inhibitors , Drug Design , Kinetics , Microbial Sensitivity Tests , beta-Lactamases
10.
Cir Esp (Engl Ed) ; 2021 Jan 29.
Article in English, Spanish | MEDLINE | ID: mdl-33610261

ABSTRACT

INTRODUCTION: The COVID-19 pandemic led to the cancellation of non-essential surgical procedures in March 2020. With the resumption of surgical activity, patients undergoing surgery were one of the first population groups to be systematically tested for PCR. The aim of this study was to determine the prevalence of asymptomatic SARS-CoV-2 carriers after the resumption of non-essential surgical activity. METHODS: Retrospective multicenter observational study of patients scheduled for surgery or undergoing emergency surgery in Catalonia between 20 April and 31 May 2020. The microbiological results of preoperative PCR tests and clinical records were reviewed, and an epidemiological survey was conducted on patients with positive PCR for SARS-CoV-2. RESULTS: A total of 10,838 patients scheduled for surgery or who underwent emergency surgery were screened for COVID-19. One hundred and eighteen patients (1.09%) were positive for SARS-CoV-2 in the 72hours prior to surgery. The prevalence of asymptomatic carriers was 0.7% (95%CI: 0.6% - 0.9%). The first week of the study presented the highest prevalence of asymptomatic carriers [1.9% (95%CI: 1.1%-3.2%)]. CONCLUSIONS: The low levels of asymptomatic carriers of COVID-19 infection obtained in the surgical population of hospitals in Catalonia after the resumption of surgical activity, shows that most patients were able to undergo surgical procedures without the risks of COVID-19 associated complications in the perioperative period.

11.
RSC Adv ; 11(17): 10364-10374, 2021 Mar 05.
Article in English | MEDLINE | ID: mdl-35423531

ABSTRACT

Corals are vulnerable to increasing ocean temperatures. It is known that elevated temperatures lead to the breakdown of an essential mutualistic relationship with photosynthetic algae. The molecular mechanisms of this temperature-dependent loss of symbiosis are less well understood. Here, the thermal stability of a critical metabolic enzyme, glyceraldehyde-3-phosphate dehydrogenase, from the stony coral Acropora millepora was found to increase significantly in the presence of its cofactor NAD+. Determination of the structure of the cofactor-enzyme complex (PDB ID 6PX2) revealed variable NAD+ occupancy across the four monomers of the tetrameric enzyme. The structure of the fully occupied monomers was compared to those with partial cofactor occupancy, identifying regions of difference that may account for the increased thermal stability.

12.
Biomed Pharmacother ; 132: 110885, 2020 Dec.
Article in English | MEDLINE | ID: mdl-33113420

ABSTRACT

The therapeutic effect of Vaccinium polyphenols against uropathogens has been widely studied. Most attention has focused on the antimicrobial activity against P-fimbriated Escherichia coli strains. The present study investigated the anti-adhesive and anti-biofilm activity of a saline extract of blueberry (Vaccinium corymbosum) targeting intestinal colonization by a highly adherent Klebsiella pneumoniae strain. This strain, responsible for a large outbreak of infection in Spain, was selected on the basis of its remarkable capacity to colonize the gastrointestinal tract of patients. The blueberry extract was obtained using a medium scale ambient temperature system (MSAT) in a novel approach based on the use of an aqueous solvent and addition of mineral salts. The polyphenolic content was determined by liquid chromatography coupled to tandem mass-spectrometry (LC-MS/MS). The findings confirmed that the blueberry extract is a rich source of phenolic compounds, including the most polar polyphenols (mostly non-flavonoids), intermediate polarity compounds (flavan-3-ols and most procyanidins) and low polarity compounds (flavonols and anthocyanins). The extract significantly inhibited biofilm formation and bacterial adhesion to HT-29 colorectal cells by a highly adherent multidrug-resistant K. pneumoniae. Although some individual anthocyanidins (malvidin, delphinidin and cyanidin) and one hydroxycinnamic acid (caffeic acid) proved capable of reducing bacterial adhesion, the unfractionated extract was more active than any of the individual polyphenolic compounds. In addition, the extract displayed considerable potential as an intestinal decolonization treatment in a murine model. The study findings demonstrate the potential value of the V. corymbosum extract as an alternative treatment for K. pneumoniae infections.


Subject(s)
Anti-Bacterial Agents/pharmacology , Bacterial Adhesion/drug effects , Biofilms/drug effects , Blueberry Plants , Intestines/microbiology , Klebsiella Infections/drug therapy , Klebsiella pneumoniae/drug effects , Plant Extracts/pharmacology , Polyphenols/pharmacology , Animals , Anti-Bacterial Agents/isolation & purification , Biofilms/growth & development , Blueberry Plants/chemistry , Disease Models, Animal , Drug Resistance, Multiple, Bacterial , Fruit , HT29 Cells , Humans , Klebsiella Infections/microbiology , Klebsiella pneumoniae/growth & development , Mice, Inbred BALB C , Plant Extracts/isolation & purification , Polyphenols/isolation & purification
13.
Biomed Pharmacother ; 130: 110606, 2020 Oct.
Article in English | MEDLINE | ID: mdl-32795924

ABSTRACT

The discovery of new antibiotics that are effective against Acinetobacter baumannii and Enterobacteralesis a research priority. Several essential oils (EOs) have displayed some antimicrobial activity and could potentially act as antibiotic adjuvants. Research in this area aims to develop new therapeutic alternatives to treat infections caused by these pathogens. MICs of different EOs were determined against A. baumannii and Klebsiella pneumoniae. Combined disk diffusion tests and checkerboard assays were used to study the synergy between the EOs and antibiotics. The fractional inhibitory concentration index (FICindex) was calculated in order to categorize the interaction. Time-kill assays were also performed. The EOs that displayed the highest levels of antimicrobial activity were clove (Syzygium aromaticum L.) and thyme (Thymus zygis L.). Combined disk diffusion tests and checkerboard assays revealed synergy between these EOs and colistin. Addition of either clove or thyme EO decreased the MIC of colistin by 8- to 64-fold and 8- to 128-fold in the colistin-resistant A. baumannii and K. pneumoniae strains, respectively (FICindex ≤ 0.5, synergy). MICs were also reduced in the colistin-susceptible strains. Time-kill assays also indicated the strong activity of the combined therapy. In summary, the use of clove or thyme EO in combination with colistin could improve the efficacy of the antibiotic and significantly reduce the concentrations needed to inhibit growth of A. baumannii and K. pneumoniae.


Subject(s)
Acinetobacter baumannii/drug effects , Anti-Bacterial Agents/pharmacology , Clove Oil/pharmacology , Colistin/pharmacology , Cross Infection/microbiology , Klebsiella pneumoniae/drug effects , Oils, Volatile/pharmacology , Syzygium/chemistry , Thymus Plant/chemistry , Drug Resistance, Multiple, Bacterial/drug effects , Drug Synergism , Humans , Microbial Sensitivity Tests
14.
Proc Natl Acad Sci U S A ; 117(29): 17249-17259, 2020 07 21.
Article in English | MEDLINE | ID: mdl-32641516

ABSTRACT

Control of infections caused by carbapenem-resistant Klebsiella pneumoniae continues to be challenging. The success of this pathogen is favored by its ability to acquire antimicrobial resistance and to spread and persist in both the environment and in humans. The emergence of clinically important clones, such as sequence types 11, 15, 101, and 258, has been reported worldwide. However, the mechanisms promoting the dissemination of such high-risk clones are unknown. Unraveling the factors that play a role in the pathobiology and epidemicity of K. pneumoniae is therefore important for managing infections. To address this issue, we studied a carbapenem-resistant ST-15 K. pneumoniae isolate (Kp3380) that displayed a remarkable adherent phenotype with abundant pilus-like structures. Genome sequencing enabled us to identify a chaperone-usher pili system (Kpi) in Kp3380. Analysis of a large K. pneumoniae population from 32 European countries showed that the Kpi system is associated with the ST-15 clone. Phylogenetic analysis of the operon revealed that Kpi belongs to the little-characterized γ2-fimbrial clade. We demonstrate that Kpi contributes positively to the ability of K. pneumoniae to form biofilms and adhere to different host tissues. Moreover, the in vivo intestinal colonizing capacity of the Kpi-defective mutant was significantly reduced, as was its ability to infect Galleria mellonella The findings provide information about the pathobiology and epidemicity of Kpi+K. pneumoniae and indicate that the presence of Kpi may explain the success of the ST-15 clone. Disrupting bacterial adherence to the intestinal surface could potentially target gastrointestinal colonization.


Subject(s)
Fimbriae, Bacterial/genetics , Klebsiella pneumoniae/genetics , Molecular Chaperones/genetics , A549 Cells , Animals , Anti-Bacterial Agents , Bacterial Adhesion/drug effects , Bacterial Adhesion/genetics , Biofilms/drug effects , Biofilms/growth & development , Carbapenems/pharmacology , Cell Line , Disease Models, Animal , Drug Resistance, Multiple, Bacterial/genetics , Epithelial Cells/microbiology , Europe , Female , Gene Deletion , Genes, Bacterial/genetics , Humans , Klebsiella Infections , Klebsiella pneumoniae/cytology , Klebsiella pneumoniae/drug effects , Mice , Mice, Inbred BALB C , Multilocus Sequence Typing , Operon , Phylogeny
15.
PLoS Pathog ; 16(2): e1008311, 2020 02.
Article in English | MEDLINE | ID: mdl-32040500

ABSTRACT

Pseudomonas aeruginosa is one of the leading causes of nosocomial pneumonia and its associated mortality. Moreover, extensively drug-resistant high-risk clones are globally widespread, presenting a major challenge to the healthcare systems. Despite this, no vaccine is available against this high-concerning pathogen. Here we tested immunogenicity and protective efficacy of an experimental live vaccine against P. aeruginosa pneumonia, consisting of an auxotrophic strain which lacks the key enzyme involved in D-glutamate biosynthesis, a structural component of the bacterial cell wall. As the amounts of free D-glutamate in vivo are trace substances in most cases, blockage of the cell wall synthesis occurs, compromising the growth of this strain, but not its immunogenic properties. Indeed, when delivered intranasally, this vaccine stimulated production of systemic and mucosal antibodies, induced effector memory, central memory and IL-17A-producing CD4+ T cells, and recruited neutrophils and mononuclear phagocytes into the airway mucosa. A significant improvement in mice survival after lung infection caused by ExoU-producing PAO1 and PA14 strains was observed. Nearly one third of the mice infected with the XDR high-risk clone ST235 were also protected. These findings highlight the potential of this vaccine for the control of acute pneumonia caused by this bacterial pathogen.


Subject(s)
Pseudomonas Infections/immunology , Pseudomonas aeruginosa/immunology , Vaccines, Attenuated/immunology , Administration, Intranasal , Animals , Antibodies, Bacterial/immunology , Female , Immunity, Mucosal , Male , Mice , Mice, Inbred BALB C , Pneumonia, Bacterial/immunology , Pseudomonas aeruginosa/metabolism , Pseudomonas aeruginosa/pathogenicity , Respiratory System/immunology , Respiratory Tract Infections/immunology , Vaccines, Attenuated/pharmacology
16.
J Antimicrob Chemother ; 74(5): 1244-1252, 2019 05 01.
Article in English | MEDLINE | ID: mdl-30753505

ABSTRACT

OBJECTIVES: To characterize the antimicrobial susceptibility, molecular epidemiology and carbapenem resistance mechanisms in Pseudomonas aeruginosa isolates recovered from respiratory tract samples from patients with ventilator-associated pneumonia enrolled in the MagicBullet clinical trial. METHODS: Isolates were collected from 53 patients from 12 hospitals in Spain, Italy and Greece. Susceptibility was determined using broth microdilution and Etest. MALDI-TOF MS was used to detect carbapenemase activity and carbapenemases were identified by PCR and sequencing. Molecular epidemiology was investigated using PFGE and MLST. RESULTS: Of the 53 isolates, 2 (3.8%) were considered pandrug resistant (PDR), 19 (35.8%) were XDR and 16 (30.2%) were MDR. Most (88.9%) of the isolates from Greece were MDR, XDR or PDR, whereas fewer of the isolates from Spain (33.3%) and Italy (43.5%) showed antibiotic resistance. Three Greek isolates were resistant to colistin. Overall, the rates of resistance of P. aeruginosa isolates to imipenem, ciprofloxacin, ceftolozane/tazobactam and ceftazidime/avibactam were 64.1%, 54.7%, 22.6% and 24.5%, respectively. All isolates resistant to ceftolozane/tazobactam and ceftazidime/avibactam (Greece, n = 10; and Italy, n = 2) carried blaVIM-2. Spanish isolates were susceptible to the new drug combinations. Forty-eight restriction patterns and 27 STs were documented. Sixty percent of isolates belonged to six STs, including the high-risk clones ST-111, ST-175 and ST-235. CONCLUSIONS: MDR/XDR isolates were highly prevalent, particularly in Greece. The most effective antibiotic against P. aeruginosa was colistin, followed by ceftolozane/tazobactam and ceftazidime/avibactam. blaVIM-2 is associated with resistance to ceftolozane/tazobactam and ceftazidime/avibactam, and related to highly resistant phenotypes. ST-111 was the most frequent and disseminated clone and the clonal diversity was lower in XDR and PDR strains.


Subject(s)
Drug Resistance, Multiple, Bacterial , Pneumonia, Ventilator-Associated/epidemiology , Pneumonia, Ventilator-Associated/etiology , Pseudomonas Infections/epidemiology , Pseudomonas Infections/etiology , Pseudomonas aeruginosa/drug effects , Bacterial Proteins/genetics , Greece/epidemiology , Humans , Incidence , Inhibitory Concentration 50 , Italy/epidemiology , Microbial Sensitivity Tests , Molecular Epidemiology , Multilocus Sequence Typing , Phylogeny , Pneumonia, Ventilator-Associated/drug therapy , Pseudomonas Infections/drug therapy , Pseudomonas aeruginosa/classification , Pseudomonas aeruginosa/genetics , Spain/epidemiology , beta-Lactam Resistance , beta-Lactamases/genetics
17.
Bioorg Chem ; 75: 217-223, 2017 12.
Article in English | MEDLINE | ID: mdl-28987877

ABSTRACT

The FIKK family of kinases is unique to parasites of the Apicomplexan order, which includes all malaria parasites. Plasmodium falciparum, the most virulent form of human malaria, has a family of 19 FIKK kinases, most of which are exported into the host red blood cell during malaria infection. Here, we confirm that FIKK 8 is a non-exported member of the FIKK kinase family. Through expression and purification of the recombinant kinase domain, we establish that emodin is a relatively high-affinity (IC50=2µM) inhibitor of PfFk8. Closely related anthraquinones do not inhibit PfFk8, suggesting that the particular substitution pattern of emodin is critical to the inhibitory pharmacophore. This first report of a P. falciparum FIKK kinase inhibitor lays the groundwork for developing specific inhibitors of the various members of the FIKK kinase family in order to probe their physiological function.


Subject(s)
Emodin/chemistry , Emodin/pharmacology , Plasmodium falciparum/enzymology , Protein Kinases/chemistry , Protein Kinases/pharmacology , Protozoan Proteins/antagonists & inhibitors , Amino Acid Sequence , Anthraquinones/chemistry , Emodin/metabolism , Enzyme Activation/drug effects , Erythrocytes/metabolism , Erythrocytes/parasitology , Humans , Inhibitory Concentration 50 , Microscopy, Fluorescence , Plasmodium falciparum/drug effects , Protein Kinase Inhibitors/chemistry , Protein Kinase Inhibitors/metabolism , Protein Kinase Inhibitors/pharmacology , Protein Kinases/genetics , Protozoan Proteins/genetics , Protozoan Proteins/metabolism , Recombinant Proteins/biosynthesis , Recombinant Proteins/chemistry , Recombinant Proteins/isolation & purification , Small Molecule Libraries/chemistry , Small Molecule Libraries/metabolism
18.
PLoS One ; 12(8): e0182084, 2017.
Article in English | MEDLINE | ID: mdl-28763494

ABSTRACT

Many strains of Acinetobacter baumannii have been described as being able to form biofilm. Small non-coding RNAs (sRNAs) control gene expression in many regulatory circuits in bacteria. The aim of the present work was to provide a global description of the sRNAs produced both by planktonic and biofilm-associated (sessile) cells of A. baumannii ATCC 17978, and to compare the corresponding gene expression profiles to identify sRNAs molecules associated to biofilm formation and virulence. sRNA was extracted from both planktonic and sessile cells and reverse transcribed. cDNA was subjected to 454-pyrosequencing using the GS-FLX Titanium chemistry. The global analysis of the small RNA transcriptome revealed different sRNA expression patterns in planktonic and biofilm associated cells, with some of the transcripts only expressed or repressed in sessile bacteria. A total of 255 sRNAs were detected, with 185 of them differentially expressed in the different types of cells. A total of 9 sRNAs were expressed only in biofilm cells, while the expression of other 21 coding regions were repressed only in biofilm cells. Strikingly, the expression level of the sRNA 13573 was 120 times higher in biofilms than in planktonic cells, an observation that prompted us to further investigate the biological role of this non-coding transcript. Analyses of an isogenic mutant and over-expressing strains revealed that the sRNA 13573 gene is involved in biofilm formation and attachment to A549 human alveolar epithelial cells. The present work serves as a basis for future studies examining the complex regulatory network that regulate biofilm biogenesis and attachment to eukaryotic cells in A. baumannii ATCC 17978.


Subject(s)
Acinetobacter baumannii/genetics , Biofilms , Gene Expression Profiling , RNA, Small Untranslated/genetics , A549 Cells , Acinetobacter baumannii/physiology , Cell Line, Tumor , DNA, Complementary/genetics , Gene Expression Regulation, Bacterial , Humans , Microscopy, Electron, Scanning , RNA, Bacterial/genetics , Virulence
19.
Nat Commun ; 8: 15480, 2017 05 26.
Article in English | MEDLINE | ID: mdl-28548079

ABSTRACT

Vaccine development is a priority for global health due to the growing multidrug resistance in bacteria. D-glutamate synthesis is essential for bacterial cell wall formation. Here we present a strategy for generating effective bacterial whole-cell vaccines auxotrophic for D-glutamate. We apply this strategy to generate D-glutamate auxotrophic vaccines for three major pathogens, Acinetobacter baumannii, Pseudomonas aeruginosa and Staphylococcus aureus. These bacterial vaccines show virulence attenuation and self-limited growth in mice, and elicit functional and cross-reactive antibodies, and cellular immunity. These responses correlate with protection against acute lethal infection with other strains of the same species, including multidrug resistant, virulent and/or high-risk clones such as A. baumannii AbH12O-A2 and Ab307-0294, P. aeruginosa PA14, and community-acquired methicillin-resistant S. aureus USA300LAC. This approach can potentially be applied for the development of live-attenuated vaccines for virtually any other bacterial pathogens, and does not require the identification of virulence determinants, which are often pathogen-specific.


Subject(s)
Bacteria/metabolism , Bacterial Infections/prevention & control , Bacterial Vaccines/immunology , Glutamic Acid/metabolism , Vaccines, Attenuated/immunology , Animals , Bacteria/genetics , Bacteria/immunology , Bacteria/pathogenicity , Drug Design , Drug Resistance, Multiple, Bacterial/immunology , Female , Humans , Immunity, Cellular/immunology , Immunogenicity, Vaccine , Male , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Sequence Deletion , Virulence/immunology
20.
Article in English | MEDLINE | ID: mdl-28536672

ABSTRACT

Introduction:Acinetobacter baumannii is an opportunistic nosocomial pathogen associated with multiple infections. This pathogen usually colonizes (first stage of microbial infection) host tissues that are in contact with the external environment. As one of the sites of entry in human hosts is the gastrointestinal tract, the pathogen must be capable of tolerating bile salts. However, studies analyzing the molecular characteristics involved in the response to bile salts in clinical strains of A. baumannii are scarce. Material and Methods: Microbiological and transcriptional studies (arrays and RT-PCR) in the response to bile salts were carried out in isogenic (A. baumanni ΔadeB ATCC 17978 and A. baumannii ΔadeL ATCC 17978) and clinical strains from clone ST79/PFGE-HUI-1 which is characterized by lacking the AdeABC efflux pump and by overexpression the AdeFGH efflux pump. Results and Discussion: In presence of bile salts, in addition to the glutamate/aspartate transporter were found overexpressed in A. baumannii ΔadeB ATCC 17978, the virulence factors (surface motility, biofilm, and Type VI Secretion System) which are associated with activation of the Quorum Sensing system. Overexpression of these factors was confirmed in clinical strains of clone ST79/PFGE-HUI-1. Conclusions: This the first study about the adaptive response to bile salts investigating the molecular and microbiological characteristics in response to bile salts of an isogenic model of A. baumannii ATCC 17978 and clinical isolates of A. baumannii (clinical strains of ST79/PFGE-HUI-1) lacking the main RND efflux pump (AdeABC). Clinical isolates of A. baumannii lacking the AdeABC efflux pump (clone ST79/PFGE-HUI-1) displayed a new clinical profile (increased invasiveness) possibly associated with the response to stress conditions (such as the presence of bile salts).


Subject(s)
Acinetobacter baumannii/drug effects , Acinetobacter baumannii/genetics , Bile Acids and Salts/pharmacology , Quorum Sensing/drug effects , Virulence/drug effects , Acinetobacter baumannii/growth & development , Acinetobacter baumannii/pathogenicity , Anti-Bacterial Agents/pharmacology , Bacterial Proteins/genetics , Biofilms/drug effects , Drug Resistance, Multiple, Bacterial , Drug Tolerance , Gastrointestinal Tract/microbiology , Gene Expression Regulation, Bacterial , Genes, Bacterial/genetics , Humans , Microbial Sensitivity Tests , Quorum Sensing/genetics , Type VI Secretion Systems/drug effects , Virulence/genetics , Virulence Factors/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...